Trials / Completed
CompletedNCT01165320
A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)
A Multicenter, Noncomparative, Open-label Study to Estimate the Safety, Efficacy, and Pharmacokinetics of MK-0991 (Caspofungin) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 3 Months – 17 Years
- Healthy volunteers
- Not accepted
Summary
The study estimates the safety, efficacy, and pharmacokinetics of caspofungin (MK-0991) in Japanese children and adolescents with documented Candida or Aspergillus infections.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Caspofungin |
Timeline
- Start date
- 2010-07-06
- Primary completion
- 2013-09-17
- Completion
- 2013-09-17
- First posted
- 2010-07-19
- Last updated
- 2018-08-27
- Results posted
- 2014-04-23
Source: ClinicalTrials.gov record NCT01165320. Inclusion in this directory is not an endorsement.